Arsenic Primes Human Bone Marrow CD34+ Cells for Erythroid Differentiation
Yuanyuan Zhang1, Shasha Wang2, Chunyan Chen3
1Key Laboratory of Cardiovascular Remodeling and Function Research, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China ; Department of Oncology and Pathology (CCK), R8:03, Karolinska University Hospital, Solna, 17176 Stockholm, Sweden.
Bioinorganic Chemistry and Applications
|July 15, 2015
Summary
Arsenic trioxide may promote blood cell differentiation. This study found it enhances erythroid differentiation in human hematopoietic progenitor cells, suggesting a novel therapeutic priming effect.
Area of Science:
- Hematology
- Cell Biology
- Oncology
Background:
- Arsenic trioxide is used to treat blood cancers by modulating cell differentiation.
- Previous studies suggested arsenic inhibits erythroid differentiation in hematopoietic progenitor cells.
- Cytostatic and cytotoxic effects of arsenic may mask its potential to promote differentiation.
Purpose of the Study:
- To investigate the effect of arsenic trioxide on erythroid differentiation, independent of its cytotoxic actions.
- To determine if arsenic trioxide can prime human hematopoietic progenitor cells for differentiation.
Main Methods:
- Human bone marrow CD34+ cells from chronic myeloid leukemia patients in remission were pretreated with non-cytotoxic arsenic trioxide.
- Colony-forming assays were performed in the absence of arsenic trioxide to assess differentiation.
- Erythroid and granulomonocytic differentiation potential was evaluated, along with erythrocyte maturation in K562 cells.
Main Results:
- Arsenic trioxide pretreatment significantly enhanced erythroid colony-forming activity.
- A decrease in granulomonocytic differentiation function was observed.
- Arsenic trioxide inhibited erythrocyte maturation in erythroleukemic K562 cells, indicating biphasic effects on erythropoiesis.
Conclusions:
- This study provides the first evidence that arsenic trioxide can prime human hematopoietic progenitor cells for enhanced erythroid differentiation.
- The findings suggest a novel mechanism for arsenic trioxide's therapeutic effects in hematological malignancies.
- Arsenic trioxide may possess biphasic effects on erythropoiesis, promoting progenitor differentiation while inhibiting terminal maturation.
